Phenacyl group containing amide derivative of dehydroabietylamine exhibiting enhanced cytotoxic activity against PLC and MCF7 cancer cell lines

• Published in: Medicinal chemistry research Vol. 26; no. 7; pp. 1367 - 1376
• Main Authors: Mustufa, Muhammad Ayaz, Aslam, Afshan, Ozen, Cigdem, Ali Hashmi, Imran, Naqvi, Naim ul Hasan, Ozturk, Mehmet, Ali, Firdous Imran
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-07-2017; Springer Nature B.V
• Subjects: Amides; Berries; Biochemistry; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer; Cell Biology; Cytotoxicity; Diterpenes; Hepatocellular carcinoma; Original Research; Pharmacology/Toxicology; Tumor cell lines; Dehydroabietylamine; Amides; NMR spectroscopy; FTIR; Cancer; Cytotoxic activity
• ISSN: 1054-2523; 1554-8120
• DOI: 10.1007/s00044-017-1859-0

New amide derivatives of (+)-dehydroabietylamine, tricyclic abietane diterpene amine, were prepared using Zhongping’s protocol. (+)-
N
-(2-phenyl-acetyl)-dehydroabietylamine derivative (
11
) demonstrated noticeable growth attenuation of hepatocellular carcinoma cell lines including PLC/PRF/5, SNU475, Hep3B-TR, and Huh7 with IC
50
of 7.4 µM, 9.8 µM, 11.7 µM, and 11.8 µM, respectively. A breast cancer cell line MCF7 was the most sensitive against amide
11
with lowest IC
50
value (4.8 µM). Low cell confluence and increase in G2/M phase was recorded after 48 and 72 h of treatment of amide
11
on PLC/PRF/5 cell line. Finally, amide
11
has comparatively sufficient therapeutic role due to addition of
N
-phenacyl group at C-18. Amide
11
demonstrated as potential candidate for future cancer interference and research.
Graphical Abstract